OXFORD, UK – 5th
November 2012 – Glide Pharma, the specialty pharmaceutical company
focused on the easy, safe and convenient administration of solid dose formulations of
therapeutics and vaccines, today announced that the UK Biomedical Catalyst has awarded
the company £2.3 million ($3.7 million) to support the development of a novel formulation of
teriparatide (parathyroid hormone) for the treatment of osteoporosis. The UK Biomedical
Catalyst, which was announced by Prime Minister David Cameron in December 2011, is
managed jointly by the Medical Research Council and the Technology Strategy Board.
Glide Pharma will use the new funding to progress its Glide SDI® teriparatide through to the
point of clinical testing. The programme will include full pre-clinical development, and will
incorporate formulation and manufacturing process development of the novel solid dose for
administration with Glide Pharma’s needle-free delivery system. Parathyroid hormone is
used to promote bone growth in osteoporosis, and is currently the most effective medical
intervention available. Glide Pharma’s needle-free solid dose teriparatide has the potential
to offer a cost-effective, patient-friendly product that avoids the cost and complexity of
“Glide Pharma is delighted to be one of the first companies to receive early stage financing
from the UK Biomedical Catalyst,” said Dr Ian Smith, Glide Pharma’s Chief Executive.
“This award recognises the great potential advantages of our Glide SDI® technology, and
the importance of offering patients an easy to use and effective osteoporosis treatment.
Medication compliance can be a significant issue in osteoporosis, and we believe our Glide
SDI treatment has the potential to become an important patient-friendly, future alternative.”
Osteoporosis is characterised by low bone density and increased susceptibility to fractures.
Approximately 55% of people aged over 50 are at risk, and the disease affects over 2 million people
in the UK and 30 million globally. Fractures can significantly affect patients’ quality of life, and in some
cases can be fatal. Hip fractures can reduce mobility and increase care requirements. Hip fractures
also have a significant impact on health budgets and cost the UK over £2 billion annually, which is
projected to rise as the population ages.
About the Glide SDI
solid dose injector
The Glide SDI® is an innovative needle-free delivery system. The reusable injector uses a spring
mechanism to administer the tiny solid dosage below the patient’s skin where it dissolves and
releases the drug to the body. Glide solid dose formulations eliminate the risk of needle-stick injuries
and avoid time-consuming reconstitution, and have the potential to modify the release of medicines if
required and improve stability, removing the need for refrigeration. The one-click action, pen-sized
device is extremely easy to use, with medicines supplied in pre-filled disposable cassettes, making it
ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI® to
traditional needle and syringe.
About Glide Pharma
Glide Pharma is a specialty pharmaceutical company focused on the easy, safe and convenient
administration of solid dose formulations of therapeutics and vaccines. The company has a range of
in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI ®. Glide Pharma has a strong management team with extensive experience of the pharmaceutical,
biotechnology and medical device sectors. The company has successfully completed four investment
rounds, and is supported by a consortium of institutional and private technology investors, including
Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.
About the Biomedical Catalyst
The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a
programme of public funding designed to deliver growth to the UK life sciences sector. Delivered
jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst
provides responsive and effective support for the best life science opportunities arising in the UK.
The programme is open to UK academics and SMEs and seeks to support those opportunities which
demonstrate the highest scientific and commercial potential, irrespective of medical area. For further
information please visit: http://www.innovateuk.org/content/competition/biomedical-catalyst.ashx